Back to results
US 2011/0256056 A1Published application
Monoclonal Antibodies Against HER2 Antigens, and Uses Therefor
AssigneeAlper Biotech, LLC
InventorÕzge Alper
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAlper Biotech, LLC
InventorÕzge Alper
Estimating the term…
The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express HER2 antigens.
An antibody for a HER2 antigen, comprising one or more of the heavy chain CDR antigen binding site sequences CDR1, CDR2 and CDR3 as set forth in FIG. 2, and one or more of the light chain CDR antigen binding site sequences CDR1, CDR2 and CDR3 as set forth in FIG. 3.
An antibody specific for a HER2 antigen, comprising one or more of a heavy chain CDR antigen binding site sequences set forth in FIG. 2, and one or more of the light chain CDR antigen binding site sequences set forth in FIG. 3.
An antibody capable of preferentially binding to a soluble form of HER2 antigen.
An isolated DNA sequence which encodes the heavy chain of an antibody molecule, wherein said antibody molecule has specificity for HER2 and wherein the variable domain of said heavy chain comprises a CDR having the antigen binding site sequences CDR1, CDR2 and CDR3 set forth in FIG. 2.
An isolated DNA sequence which encodes the light chain of an antibody molecule, wherein said antibody molecule has specificity for HER2 and further wherein the variable domain of said light chain comprises a CDR having the antigen binding site sequences CDR1, CDR2, and CDR3 set forth in FIG. 3.
A kit for the immunohistochemical detection of carcinoma comprising:
An immunoassay for detecting a HER2 antigen which binds to a monoclonal antibody having one or more of the heavy chain CDR antigen binding site sequences set forth in FIG. 2, and one or more of the light chain CDR antigen binding site sequences set forth in FIG. 3 in a sample comprising:
A method for diagnosing cancer in humans comprising:
A method for developing drugs useful in treating and/or diagnosing diseases characterized by the expression of gene products of HER2 and homologues thereof, comprising the steps of:
A method of determining the status of a cell in a sample comprising:
A method of determining the status of a cell in a sample comprising:
An antibody capable of binding to a soluble form of HER2 with a specific affinity of between 10−8 M and 10−11 M.
An antibody capable of binding a soluble form of HER2.
An antibody capable of selectively reducing the activity of a soluble HER2.
A method of determining the status of patient in need thereof by:
An antibody capable of preferentially binding to a secreted form of HER2 antigen.
An immunohistochemical method of detecting breast cancer in a tissue specimen collected from patients comprising the steps of
A composition comprising:
Dependencies are inferred from the claim text.